Congrong Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Congrong Liu has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Yuxiang Wang
Department of Pathology, Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
12 shared publicationsYan Liu
Department of Pathology, Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China
11 shared publicationsJing Yang
Department of Pathology, Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
7 shared publicationsAjin Hu
Department of Pathology, Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
6 shared publicationsCaixia Ren
Department of Histology and Embryology, Peking University Health Science Center, Beijing, 100191, China
4 shared publicationsJie Lin
Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China
4 shared publications
Latest Publications
- 22 October 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
The Largest Cohort Study of Intravenous Leiomyomatosis Reveals HMGA2 and Collagen Gene Alterations as Cooperative Drivers
Intravenous leiomyomatosis (IVL) is a rare, hormonally responsive smooth muscle neoplasm defined by nondestructive intravascular growth. Despite its distinct clinical behavior, the comprehensive molecular landscape of IVL has not been systematically characterized. We collected the clinicopathologic characteristics of 89 IVLs, 106 conventional uterine leiomyomas (cULMs), and 83 cellular leiomyomas (CLs). Using immunohistochemistry (IHC), we evaluated high mobility group AT-hook 2 (HMGA2) expression in 88 IVLs, 106 cULMs, and 83 CLs. We also assessed fumarate hydratase (FH) and 2-succinocysteine status by IHC in 82 IVLs. Fluorescence in situ hybridization was performed using the HMGA2 break-apart probe in 84 IVLs and the HMGA2/RAD51B fusion probe in 83 IVLs. We detected MED12 exon 2 hotspot mutations by Sanger sequencing in 79 IVLs. Whole-exome sequencing (WES) was performed in 10 IVLs. We found that IVL predominantly affected reproductive-aged women, most with a history of uterine trauma. HMGA2 expression was upregulated in 87.5% (77/88) of IVLs, with strong immunoreactivity in 40.9% (36/88) of IVLs. Half of IVLs harbored HMGA2 rearrangements, predominantly the HMGA2/RAD51B fusion. WES revealed frequent mutations in collagen (COL) gene family members (70.0%, 7/10), all co-occurring with HMGA2 upregulation. Conversely, MED12 exon 2 mutations (2.5%, 2/79) and FH deficiency (2.4%, 2/82) were rare events in this cohort. We propose that IVL pathogenesis likely involves synergistic interplay between dysregulated HMGA2 and COL gene family alterations within a permissive microenvironment influenced by hormones and uterine trauma. FH deficiency and MED12 exon 2 hotspot mutations appear infrequent in IVL and may not represent primary drivers of disease initiation.
- 22 October 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
The Largest Cohort Study of Intravenous Leiomyomatosis Reveals HMGA2 and Collagen Gene Alterations as Cooperative Drivers
Intravenous leiomyomatosis (IVL) is a rare, hormonally responsive smooth muscle neoplasm defined by nondestructive intravascular growth. Despite its distinct clinical behavior, the comprehensive molecular landscape of IVL has not been systematically characterized. We collected the clinicopathologic characteristics of 89 IVLs, 106 conventional uterine leiomyomas (cULMs), and 83 cellular leiomyomas (CLs). Using immunohistochemistry (IHC), we evaluated high mobility group AT-hook 2 (HMGA2) expression in 88 IVLs, 106 cULMs, and 83 CLs. We also assessed fumarate hydratase (FH) and 2-succinocysteine status by IHC in 82 IVLs. Fluorescence in situ hybridization was performed using the HMGA2 break-apart probe in 84 IVLs and the HMGA2/RAD51B fusion probe in 83 IVLs. We detected MED12 exon 2 hotspot mutations by Sanger sequencing in 79 IVLs. Whole-exome sequencing (WES) was performed in 10 IVLs. We found that IVL predominantly affected reproductive-aged women, most with a history of uterine trauma. HMGA2 expression was upregulated in 87.5% (77/88) of IVLs, with strong immunoreactivity in 40.9% (36/88) of IVLs. Half of IVLs harbored HMGA2 rearrangements, predominantly the HMGA2/RAD51B fusion. WES revealed frequent mutations in collagen (COL) gene family members (70.0%, 7/10), all co-occurring with HMGA2 upregulation. Conversely, MED12 exon 2 mutations (2.5%, 2/79) and FH deficiency (2.4%, 2/82) were rare events in this cohort. We propose that IVL pathogenesis likely involves synergistic interplay between dysregulated HMGA2 and COL gene family alterations within a permissive microenvironment influenced by hormones and uterine trauma. FH deficiency and MED12 exon 2 hotspot mutations appear infrequent in IVL and may not represent primary drivers of disease initiation.
- 9 December 2025
- Published by Elsevier in Human Pathology
- Vol. 167, 106003
Ovarian GLI1 fusion tumors mimicking sex cord-stromal Tumors: Clinicopathological and molecular characterization of a five-case series
- 9 December 2025
- Published by Elsevier in Human Pathology
- Vol. 167, 106003
Ovarian GLI1 fusion tumors mimicking sex cord-stromal Tumors: Clinicopathological and molecular characterization of a five-case series
- Open Access
- 29 November 2025
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 12 (1) , e70055
Decoding UTROSCT heterogeneity: systematic clinicopathological evaluation combined with molecular profiling
Uterine tumor resembling ovarian sex cord tumor (UTROSCT) constitutes an exceptionally rare histological subset of uterine mesenchymal neoplasms. While most cases have benign clinical behavior, a subset of UTROSCTs exhibits clinically aggressive behavior characterized by recurrence and metastasis. Here, we present a cohort of 25 UTROSCT cases molecularly confirmed by recurrent fusion gene detection, including ESR1::NCOA3 ( n = 12), GREB1::NCOA1 ( n = 6), ESR1::NCOA2 ( n = 3), GREB1::NCOA2 ( n = 2), GREB1::SS18 ( n = 1), and GREB1::CTNNB1 ( n = 1). Notably, six cases (6/25, 24%) demonstrated recurrence/metastasis: two cases showed intrauterine recurrence (harboring ESR1::NCOA3 and GREB1::NCOA1 fusions), while four developed extrauterine metastases (carrying ESR1::NCOA3 , ESR1::NCOA2, GREB1::NCOA1, and GREB1::NCOA2 fusions), with one fatality. To dissect the biological basis of UTROSCT aggressiveness, we performed integrated clinicopathologic, immunohistochemical, and molecular profiling. Multivariate analysis identified tumor size >5 cm, FIGO stage IB, and lymphovascular space invasion (LVSI) as independent predictors of recurrence/metastasis, whereas histologic features, proliferation index, and fusion gene subtypes lacked prognostic significance. Multi‐omics analysis of primary versus metastatic tumors revealed striking copy number variations (CNVs) exclusively in metastatic lesions. Specifically, heterozygous losses of SMARCB1 (2/4 metastatic cases) and ATRX (1/4 metastatic cases) were identified; both play critical roles in chromatin remodeling. These genetic alterations were conspicuously absent in primary tumors, suggesting their potential role in metastatic progression. Our findings represent the first demonstration of CNV‐driven oncogenic evolution in UTROSCTs, particularly implicating SWI/SNF complex dysregulation in metastatic competence.
- 29 November 2025
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 12 (1) , e70055
Open AccessDecoding UTROSCT heterogeneity: systematic clinicopathological evaluation combined with molecular profiling
Uterine tumor resembling ovarian sex cord tumor (UTROSCT) constitutes an exceptionally rare histological subset of uterine mesenchymal neoplasms. While most cases have benign clinical behavior, a subset of UTROSCTs exhibits clinically aggressive behavior characterized by recurrence and metastasis. Here, we present a cohort of 25 UTROSCT cases molecularly confirmed by recurrent fusion gene detection, including ESR1::NCOA3 ( n = 12), GREB1::NCOA1 ( n = 6), ESR1::NCOA2 ( n = 3), GREB1::NCOA2 ( n = 2), GREB1::SS18 ( n = 1), and GREB1::CTNNB1 ( n = 1). Notably, six cases (6/25, 24%) demonstrated recurrence/metastasis: two cases showed intrauterine recurrence (harboring ESR1::NCOA3 and GREB1::NCOA1 fusions), while four developed extrauterine metastases (carrying ESR1::NCOA3 , ESR1::NCOA2, GREB1::NCOA1, and GREB1::NCOA2 fusions), with one fatality. To dissect the biological basis of UTROSCT aggressiveness, we performed integrated clinicopathologic, immunohistochemical, and molecular profiling. Multivariate analysis identified tumor size >5 cm, FIGO stage IB, and lymphovascular space invasion (LVSI) as independent predictors of recurrence/metastasis, whereas histologic features, proliferation index, and fusion gene subtypes lacked prognostic significance. Multi‐omics analysis of primary versus metastatic tumors revealed striking copy number variations (CNVs) exclusively in metastatic lesions. Specifically, heterozygous losses of SMARCB1 (2/4 metastatic cases) and ATRX (1/4 metastatic cases) were identified; both play critical roles in chromatin remodeling. These genetic alterations were conspicuously absent in primary tumors, suggesting their potential role in metastatic progression. Our findings represent the first demonstration of CNV‐driven oncogenic evolution in UTROSCTs, particularly implicating SWI/SNF complex dysregulation in metastatic competence.
- 1 October 2025
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 80, 152567
Accuracy and clinical value of intraoperative frozen section assessment in endometrial carcinoma
- 1 October 2025
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 80, 152567
Accuracy and clinical value of intraoperative frozen section assessment in endometrial carcinoma
- Open Access
Prognostic value of lymphocyte-to-monocyte ratio in patients with endometrial cancer: an updated systematic review and meta-analysis
Background: Evaluating the risk of metastasis at diagnosis and the likelihood of future recurrence is crucial for the effective management of endometrial cancer (EC). While conventional prognostic indicators hold importance, they often fall short in predicting recurrence, especially in low-risk patients. This study evaluates the prognostic value of the lymphocyte-to-monocyte ratio (LMR) for overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS) in EC patients. Methods: Eligible studies that provided pretreatment cutoff values of LMR, hazard ratios (HRs), and 95% confidence intervals (CIs) for OS, DFS, CSS, and progression-free survival (PFS) were included in this meta-analysis. Two independent reviewers collected and evaluated the data, and the quality of the included studies was assessed using the Newcastle Ottawa Quality Assessment Scale (NOS). Statistical analyses were performed using STATA software, and subgroup analyses were conducted by race, sample size, and age to assess the consistency of LMR’s prognostic value across different population groups. Results: In this meta-analysis, eight studies were included for OS (1,997 patients) and five studies were included for DFS (1,590 patients). LMR was significantly associated with OS (HR 2.29; 95% CI [1.50–3.51]; p = 0.0014), DFS (HR 4.00; 95% CI [1.76–9.07]; p = 0.0094), and CSS (HR, 1.58; 95% CI [1.11–2.25]; p = 0.01). Subgroup analysis indicated that the prognostic value of LMR for OS was consistent across different races, age groups, and sample sizes. However, the correlation between LMR and DFS was influenced by median age, with younger patients (<60 years) showing a stronger association. Sensitivity analyses confirmed the robustness of these results, and Egger’s test showed no significant publication bias. Discussion: LMR serves as a valuable prognostic marker for OS, DFS, and CSS in EC patients. Its predictive power remains significant across diverse population groups, underscoring its potential utility in clinical practice. Biological mechanisms linking inflammation and cancer support the role of LMR in prognosis, given the functions of lymphocytes and monocytes in tumor progression and immune response. These findings suggest that incorporating LMR into current prognostic models could enhance risk stratification for EC patients, particularly for identifying those at higher risk of recurrence despite being classified as low risk by traditional systems. In conclusion, LMR is a robust, independent prognostic factor for EC, with significant implications for improving patient management and outcomes through better risk stratification.
Open AccessPrognostic value of lymphocyte-to-monocyte ratio in patients with endometrial cancer: an updated systematic review and meta-analysis
Background: Evaluating the risk of metastasis at diagnosis and the likelihood of future recurrence is crucial for the effective management of endometrial cancer (EC). While conventional prognostic indicators hold importance, they often fall short in predicting recurrence, especially in low-risk patients. This study evaluates the prognostic value of the lymphocyte-to-monocyte ratio (LMR) for overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS) in EC patients. Methods: Eligible studies that provided pretreatment cutoff values of LMR, hazard ratios (HRs), and 95% confidence intervals (CIs) for OS, DFS, CSS, and progression-free survival (PFS) were included in this meta-analysis. Two independent reviewers collected and evaluated the data, and the quality of the included studies was assessed using the Newcastle Ottawa Quality Assessment Scale (NOS). Statistical analyses were performed using STATA software, and subgroup analyses were conducted by race, sample size, and age to assess the consistency of LMR’s prognostic value across different population groups. Results: In this meta-analysis, eight studies were included for OS (1,997 patients) and five studies were included for DFS (1,590 patients). LMR was significantly associated with OS (HR 2.29; 95% CI [1.50–3.51]; p = 0.0014), DFS (HR 4.00; 95% CI [1.76–9.07]; p = 0.0094), and CSS (HR, 1.58; 95% CI [1.11–2.25]; p = 0.01). Subgroup analysis indicated that the prognostic value of LMR for OS was consistent across different races, age groups, and sample sizes. However, the correlation between LMR and DFS was influenced by median age, with younger patients (<60 years) showing a stronger association. Sensitivity analyses confirmed the robustness of these results, and Egger’s test showed no significant publication bias. Discussion: LMR serves as a valuable prognostic marker for OS, DFS, and CSS in EC patients. Its predictive power remains significant across diverse population groups, underscoring its potential utility in clinical practice. Biological mechanisms linking inflammation and cancer support the role of LMR in prognosis, given the functions of lymphocytes and monocytes in tumor progression and immune response. These findings suggest that incorporating LMR into current prognostic models could enhance risk stratification for EC patients, particularly for identifying those at higher risk of recurrence despite being classified as low risk by traditional systems. In conclusion, LMR is a robust, independent prognostic factor for EC, with significant implications for improving patient management and outcomes through better risk stratification.
- 25 January 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 186, 109713
OCDet: A comprehensive ovarian cell detection model with channel attention on immunohistochemical and morphological pathology images
- 25 January 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 186, 109713
OCDet: A comprehensive ovarian cell detection model with channel attention on immunohistochemical and morphological pathology images
- Open Access
- 22 January 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (2) , e70620
Exploring Cervical Adenocarcinoma: Epidemiological Insights, Diagnostic and Therapeutic Challenges, and Pathogenetic Mechanisms
Background: Cervical cancer poses a significant threat to women's health and encompasses various histological types, including squamous cell carcinoma (SCC), cervical adenocarcinoma (CA), and adenosquamous carcinoma. CA, in particular, presents a formidable challenge in clinical management due to its low early detection rate, pronounced aggressiveness, high recurrence rate, and mortality, compounded by the complexities associated with late‐stage treatment. There is limited understanding of the similarities and differences in the pathogenesis mechanisms between CA and SCC, such as tumor heterogeneity and the tumor immune microenvironment (TME).Methods: A literature search was carried out in the PubMed, Web of Science, and Google Scholar databases using the following research terms: “gynecological oncology,” “cervical cancer,” “cervical adenocarcinoma,” “epidemiology,” “diagnosis and treatment of cervical adenocarcinoma,” “Human papillomavirus,” “World Health Organization,” “tumor microenvironment,” “single‐cell RNA sequencing,” “molecular mechanism,” and “preclinical research model.”Conclusion: This review consolidates the epidemiological characteristics, diagnostic and therapeutic hurdles, and the latest advances in research on CA. It aims to highlight the significant heterogeneity of the TME characteristics exhibited by CA compared to SCC. Additionally, we also summarize the common preclinical models for CA and discuss the advantages and disadvantages of using various models in research. We aspire that the discussions presented herein will offer novel insights and directions for subsequent research, as well as clinical diagnosis and treatment strategies for CA.
- 22 January 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (2) , e70620
Open AccessExploring Cervical Adenocarcinoma: Epidemiological Insights, Diagnostic and Therapeutic Challenges, and Pathogenetic Mechanisms
Background: Cervical cancer poses a significant threat to women's health and encompasses various histological types, including squamous cell carcinoma (SCC), cervical adenocarcinoma (CA), and adenosquamous carcinoma. CA, in particular, presents a formidable challenge in clinical management due to its low early detection rate, pronounced aggressiveness, high recurrence rate, and mortality, compounded by the complexities associated with late‐stage treatment. There is limited understanding of the similarities and differences in the pathogenesis mechanisms between CA and SCC, such as tumor heterogeneity and the tumor immune microenvironment (TME).Methods: A literature search was carried out in the PubMed, Web of Science, and Google Scholar databases using the following research terms: “gynecological oncology,” “cervical cancer,” “cervical adenocarcinoma,” “epidemiology,” “diagnosis and treatment of cervical adenocarcinoma,” “Human papillomavirus,” “World Health Organization,” “tumor microenvironment,” “single‐cell RNA sequencing,” “molecular mechanism,” and “preclinical research model.”Conclusion: This review consolidates the epidemiological characteristics, diagnostic and therapeutic hurdles, and the latest advances in research on CA. It aims to highlight the significant heterogeneity of the TME characteristics exhibited by CA compared to SCC. Additionally, we also summarize the common preclinical models for CA and discuss the advantages and disadvantages of using various models in research. We aspire that the discussions presented herein will offer novel insights and directions for subsequent research, as well as clinical diagnosis and treatment strategies for CA.
- Open Access
- 27 December 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Single-cell profiling reveals the intratumor heterogeneity and immunosuppressive microenvironment in cervical adenocarcinoma
Background Cervical adenocarcinoma (ADC) is more aggressive compared to other types of cervical cancer (CC), such as squamous cell carcinoma (SCC). The tumor immune microenvironment (TIME) and tumor heterogeneity are recognized as pivotal factors in cancer progression and therapy. However, the disparities in TIME and heterogeneity between ADC and SCC are poorly understood. Methods We performed single-cell RNA sequencing on 11 samples of ADC tumor tissues, with other 4 SCC samples served as controls. The immunochemistry and multiplexed immunofluorescence were conducted to validate our findings. Results Compared to SCC, ADC exhibited unique enrichments in several sub-clusters of epithelial cells with elevated stemness and hyper-malignant features, including the Epi_10_CYSTM1 cluster. ADC displayed a highly immunosuppressive environment characterized by the enrichment of regulatory T cells (Tregs) and tumor-promoting neutrophils. The Epi_10_CYSTM1 cluster recruits Tregs via ALCAM-CD6 signaling, while Tregs reciprocally induce stemness in the Epi_10_CYSTM1 cluster through TGFβ signaling. Importantly, our study revealed that the Epi_10_CYSTM1 cluster could serve as a valuable predictor of lymph node metastasis for CC patients. Conclusions This study highlights the significance of ADC-specific cell clusters in establishing a highly immunosuppressive microenvironment, ultimately contributing to the heightened aggressiveness and poorer prognosis of ADC compared to SCC.
- 27 December 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessSingle-cell profiling reveals the intratumor heterogeneity and immunosuppressive microenvironment in cervical adenocarcinoma
Background Cervical adenocarcinoma (ADC) is more aggressive compared to other types of cervical cancer (CC), such as squamous cell carcinoma (SCC). The tumor immune microenvironment (TIME) and tumor heterogeneity are recognized as pivotal factors in cancer progression and therapy. However, the disparities in TIME and heterogeneity between ADC and SCC are poorly understood. Methods We performed single-cell RNA sequencing on 11 samples of ADC tumor tissues, with other 4 SCC samples served as controls. The immunochemistry and multiplexed immunofluorescence were conducted to validate our findings. Results Compared to SCC, ADC exhibited unique enrichments in several sub-clusters of epithelial cells with elevated stemness and hyper-malignant features, including the Epi_10_CYSTM1 cluster. ADC displayed a highly immunosuppressive environment characterized by the enrichment of regulatory T cells (Tregs) and tumor-promoting neutrophils. The Epi_10_CYSTM1 cluster recruits Tregs via ALCAM-CD6 signaling, while Tregs reciprocally induce stemness in the Epi_10_CYSTM1 cluster through TGFβ signaling. Importantly, our study revealed that the Epi_10_CYSTM1 cluster could serve as a valuable predictor of lymph node metastasis for CC patients. Conclusions This study highlights the significance of ADC-specific cell clusters in establishing a highly immunosuppressive microenvironment, ultimately contributing to the heightened aggressiveness and poorer prognosis of ADC compared to SCC.
- Open Access
- 25 July 2024
- Published by Elsevier in Laboratory Investigation
- Vol. 37 (10) , 100569
The Clinicopathological and Molecular Characteristics of Endocervical Gastric-Type Adenocarcinoma and the Use of Claudin18.2 as a Potential Therapeutic Target
- 25 July 2024
- Published by Elsevier in Laboratory Investigation
- Vol. 37 (10) , 100569
Open AccessThe Clinicopathological and Molecular Characteristics of Endocervical Gastric-Type Adenocarcinoma and the Use of Claudin18.2 as a Potential Therapeutic Target